Effectiveness and practical uses of 23-valent pneumococcal polysaccharide vaccine in healthy and special populations

被引：16
作者：
Wang, Yang [1 ]
Li, Jingxin [2 ]
Wang, Yuxiao [1 ]
Gu, Wei [3 ]
Zhu, Fengcai [1 ,2 ]
机构：
[1] Southeast Univ, Sch Publ Hlth, Nanjing, Jiangsu, Peoples R China
[2] Jiangsu Prov Ctr Dis Control & Prevent, Nanjing, Jiangsu, Peoples R China
[3] Nanjing Med Univ, Sch Publ Hlth, Nanjing, Jiangsu, Peoples R China
来源：
HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2018年 / 14卷 / 04期
关键词：
clinical trials; high-risk population; immunization strategy; pneumococcal polysaccharide vaccine; vaccine efficacy; CHRONIC LYMPHOCYTIC-LEUKEMIA; ACUTE MYOCARDIAL-INFARCTION; WORKING-AGE ADULTS; CONJUGATE VACCINE; STREPTOCOCCUS-PNEUMONIAE; MATERNAL IMMUNIZATION; ADVISORY-COMMITTEE; COST-EFFECTIVENESS; CLINICAL EFFECTIVENESS; DISEASE EPIDEMIOLOGY;
D O I：
10.1080/21645515.2017.1409316
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Streptococcus pneumonia (S. pneumoniae) is responsible for significant morbidity and mortality throughout the world. The 23-valent pneumococcal polysaccharide vaccines (PPV23) have been widely used for many years, but challenges are remaining in some respects, especially for its effectiveness among high-risk populations and older adults. This review aims to summarize recent clinical trials and studies of PPV23 vaccination among healthy people >= 2 years of age and those with high-risk conditions such as pregnant women, individuals with immunocompromising diseases and other chronic conditions, and provide health officials in China and other developing countries a comprehensive understanding of the current vaccination strategies for PPV23 and for the combined use of PPV23 and pneumococcal conjugate vaccines (PCVs) in adults.
引用
收藏
页码：1003 / 1012
页数：10
相关论文
共 50 条
  • [21] Vaccine profile of PPV23: Beijing Minhai Biotech 23-valent pneumococcal vaccine
    Liang, Qi
    Li, Gui-Fan
    Zhu, Feng-Cai
    EXPERT REVIEW OF VACCINES, 2016, 15 (11) : 1351 - 1359
  • [22] Cost-effectiveness and Health Benefits of Pediatric 23-valent Pneumococcal Polysaccharide Vaccine, 7-valent Pneumococcal Conjugate Vaccine and Forecasting 13-valent Pneumococcal Conjugate Vaccine in China
    Mo, Xiuting
    Tobe, Ruoyan Gai
    Liu, Xiaoyan
    Mori, Rintaro
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2016, 35 (11) : E353 - E361
  • [23] Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea
    Choi, Min-Joo
    Kang, Shin-On
    Oh, Jin-Jeong
    Park, Seong-Beom
    Kim, Min-Ja
    Cheong, Hee-Jin
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (08) : 1914 - 1922
  • [24] Cost-effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK
    Jiang, Yiling
    Gauthier, Aline
    Keeping, Sam
    Carroll, Stuart
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (06) : 913 - 927
  • [25] Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine in adults in Portugal versus "no vaccination" and versus vaccination with the 23-valent pneumococcal polysaccharide vaccine
    Gouveia, Miguel
    Jesus, Goncalo
    Ines, Monica
    Costa, Joao
    Borges, Margarida
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (04) : 850 - 858
  • [26] Rethinking results from the Japanese 23-valent pneumococcal polysaccharide vaccine randomized clinical trial
    Gessner, Bradford D.
    Theilacker, Christian
    Jodar, Luis
    VACCINE, 2019, 37 (35) : 4853 - 4857
  • [27] Pneumococcal Nasopharyngeal Carriage following Reduced Doses of a 7-Valent Pneumococcal Conjugate Vaccine and a 23-Valent Pneumococcal Polysaccharide Vaccine Booster
    Russell, F. M.
    Carapetis, J. R.
    Satzke, C.
    Tikoduadua, L.
    Waqatakirewa, L.
    Chandra, R.
    Seduadua, A.
    Oftadeh, S.
    Cheung, Y. B.
    Gilbert, G. L.
    Mulholland, E. K.
    CLINICAL AND VACCINE IMMUNOLOGY, 2010, 17 (12) : 1970 - 1976
  • [28] Antibody response to the 23-valent pneumococcal polysaccharide vaccine after conjugate vaccine in patients with chronic lymphocytic leukemia
    Lindstrom, Vesa
    Aittoniemi, Janne
    Salmenniemi, Urpu
    Kayhty, Helena
    Huhtala, Heini
    Sinisalo, Marjatta
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (12) : 2910 - 2913
  • [29] Recommendations for the use of the 23-valent polysaccharide pneumococcal vaccine in adults: A Belgian consensus report
    Peetermans, WE
    Van de Vyver, N
    Van Laethem, Y
    Van Damme, P
    Thiry, N
    Trefois, P
    Geerts, P
    Schetgen, M
    Peleman, R
    Swennen, B
    Verhaegen, J
    ACTA CLINICA BELGICA, 2005, 60 (06) : 329 - 337
  • [30] Efficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and noninvasive pneumococcal disease and related outcomes: a review of available evidence
    Niederman, Michael S.
    Folaranmi, Temitope
    Buchwald, Ulrike K.
    Musey, Luwy
    Cripps, Allan W.
    Johnson, Kelly D.
    EXPERT REVIEW OF VACCINES, 2021, 20 (03) : 243 - 255
12345